Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

AZD8055 enhances in vivo efficacy of afatinib in chordomas

The Journal of Pathology(2021)10.1002/path.5739Source: DataRank Database

AZD8055 enhances in vivo efficacy of afatinib in chordomas is a research paper published in The Journal of Pathology (2021). On theSindex it has a DataRank of 0. It has been cited 19 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access19 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.39)OA: hybridTopics (50)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (13)

I‐Mei Siu,Tara Williamson ORCID,Haoyu Zhang ORCID,Chenchen Ji ORCID,Peter C. Burger ORCID

Live enrichment

PubMed:34124783 PMC:PMC9534552 OpenAlex:https://openalex.org/W3168004909

Intramural NIH HHS

Grant: Z99 TR999999

NCI NIH HHS

Grant: U01 CA231776

National Institutes of Health

Grant: 1U01CA231776-01

Bioinformatic-Chemical Approach to Credential Molecular Targets to Combat Rapid Chemo-Radiation Resistance in SCLC

Chordoma Foundation

FWCI

1.39

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1002/path.5739

publisherhttps://doi.org/10.1002/path.5739

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/path.5739

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/path.5739

publisherhttps://pathsocjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/path.5739

Fields of Study

Bone Tumor Diagnosis and TreatmentsSarcoma Diagnosis and TreatmentOral and Maxillofacial Pathology0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

AfatinibAnimalsAntineoplastic Combined Chemotherapy ProtocolsChordomaDrug Screening Assays, AntitumorDrug SynergismHumansMorpholinesXenograft Model Antitumor AssaysCell ProliferationMice

Keywords

AfatinibCrizotinibErlotinibChordomaIn vivoPI3K/AKT/mTOR pathwayCancer researchMedicineEGFR inhibitorsViability assayPharmacologyBiologyCell cultureEpidermal growth factor receptorInternal medicinePathologySignal transductionCancerCell biologyEGFRMtorPreclinical ModelsSmall Molecule InhibitorsChordomasMorpholinesDrug SynergismXenograft Model Antitumor AssaysMiceAntineoplastic Combined Chemotherapy ProtocolsAnimalsHumansDrug Screening Assays, AntitumorCell Proliferation

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

AZD8055 enhances in vivo efficacy of afatinib in chordomas

FAIR Checklist

Authors (13)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)